A call for a consortium for optimal management of drug–drug interactions in patient care

During clinical development of medicines, manufacturers are obliged to assess the risk of drug–drug interactions (DDIs) with their new drug. There is no doubt that product labels of drugs that are nowadays introduced to the market contain much more information on DDIs than in the past. Indeed, the drug label is often the first source for DDIs available to physicians and pharmacists. But how informative are the data presented in the drug labels?.